<DOC>
	<DOCNO>NCT00245024</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use sulindac may prevent breast cancer . PURPOSE : This randomized phase I trial study effect sulindac , prevent breast cancer , woman high risk breast cancer .</brief_summary>
	<brief_title>Sulindac Preventing Breast Cancer Women High Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine partition sulindac metabolite woman high risk breast cancer measure drug metabolite level nipple aspirate fluid ( NAF ) 6 week therapy . Secondary - Determine prostaglandin level NAF patient treat drug . - Determine NAG-1 level induce NAF patient treat drug . - Determine C-reactive protein level reduce NAF patient treat drug . - Determine NAG-1 level and/or karyometric feature ductal epithelial cell modulate patient treated drug . OUTLINE : This randomize , open-label study . Patients undergo nipple aspirate fluid ( NAF ) collection . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sulindac daily . - Arm II : Patients receive oral sulindac twice daily . In arm , treatment continue 6 week absence disease progression unacceptable toxicity . All patient undergo second NAF collection . After completion study treatment , patient follow 2 week . PROJECTED ACCRUAL : A total 30 patient ( 15 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Gail assessment score &gt; 1.7 % risk 5 year History lobular carcinoma situ ( pathology report require ) History ductal carcinoma situ ( DCIS ) ( pathology report require ) History breast cancer ≥ 1 firstdegree relative history BRCA1 BRCA2 positivity treat oophorectomy mastectomy ( test report require ) History breast cancer ≥ 2 seconddegree relative Any family history breast cancer diagnose prior age 50 Personal history breast cancer ( invasive DCIS ) 1 breast intact Nipple aspirate fluid production ≥ 5 microliters Negative mammogram breast cancer within past 10 month Any suspicious breast mass must examine clinical professional Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Sex Female Menopausal status Pre postmenopausal Performance status Karnofsky 80100 % Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No history bleed clot disorder Hepatic Bilirubin ≤ 2.0 mg/dL AST ALT ≤ 2.0 time upper limit normal No indication abnormal liver function Renal Creatinine normal Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal No frequent , chronic , moderate/severe gastric complaint No upper gastrointestinal problem ( e.g. , symptom heartburn , dyspepsia , abdominal pain ) require prescription nonprescription medical remedy per week ( average ) No history peptic ulcer occult gross intestinal bleeding Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction ( e.g. , urticaria , asthma , rhinitis ) gastric intolerance attribute compound similar chemical biological composition sulindac No history allergy attribute lidocaine , EMLA® cream , xylocaine No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No 23 serving alcohol per week study participation PRIOR CONCURRENT THERAPY : Chemotherapy More 6 month since prior chemotherapy breast cancer ( invasive DCIS ) Endocrine therapy More 6 month since prior hormonal therapy breast cancer ( invasive DCIS ) No concurrent hormonesuppressing agent ( e.g. , tamoxifen anastrozole ) No concurrent selective estrogenreceptor modulators No concurrent aromatase inhibitor Radiotherapy More 6 month since prior radiotherapy breast cancer ( invasive DCIS ) Surgery See Disease Characteristics No prior breast ductdisrupting surgery ( e.g. , mastectomy ) would preclude ductoscopy Other More 3 month since prior warfarin systemic anticoagulant More 46 week since prior nonsteroidal antiinflammatory drug No concurrent phenytoin sulfonamides No concurrent warfarin systemic anticoagulant No concurrent nonsteroidal antiinflammatory drug ( include lowdose aspirin ) No concurrent large dos supplement , vitamin ( &gt; regular daily multivitamin ) and/or herbal medicine ( e.g. , echinacea , ginkgo biloba , Hypericum perforatum [ St. John 's wort ] , herbal tea ) No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>